Prior notification of a concentration (Case M.10452 — CPP Investments/FountainVest/ Langdi Pharmaceutical) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 365/04
Date: 2021-09-10
Institutions: Directorate-General for Competition, European Commission
Subjects: economic concentration, investment company, merger control, pharmaceutical industry








C_2021365EN.01000501.xml










10.9.2021   


EN


Official Journal of the European Union


C 365/5






Prior notification of a concentration
(Case M.10452 — CPP Investments/FountainVest/
Langdi Pharmaceutical)
Candidate case for simplified procedure
(Text with EEA relevance)
(2021/C 365/04)

1.   
On 2 September 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Canada Pension Plan Investment Board (‘CPP Investments’, Canada),










—


FountainVest Capital Partners GP4 Ltd. (‘FountainVest’, Cayman Islands), and










—


Beijing Zhendong Langdi Pharmaceutical Co., Ltd. And its subsidiaries (‘Langdi Pharmaceutical’, China).




CPP Investments and FountainVest acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Langdi Pharmaceutical.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are:






—


CPP Investments is a professional investment management organisation that invests in public equities, private equities, real estate, infrastructure and fixed income instruments.










—


FountainVest is an independent private equity firm. Sectors of focus include consumer, media & technology, healthcare, industrials, and financial services.










—


Langdi Pharmaceutical is a pharmaceutical company mainly active in the production and supply of calcium supplements for children, pregnant and lactating women, menopausal women and elderly people, to help prevent and treat osteoporosis, which are registered as over-the-counter (OTC) products.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10452 — CPP Investments/FountainVest/Langdi Pharmaceutical
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.